BAUSCH Health

News Releases

Register for email alerts.

All Categories

Archive

Date 12/15/14

Title

Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance

Download PDF

Date 11/28/14

Title

Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018

Download PDF

Date 11/25/14

Title

Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris

Download PDF

Date 11/20/14

Title

Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program

Download PDF

Date 11/17/14

Title

Valeant Comments On Allergan Announcement

Download PDF

Date 11/13/14

Title

Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey

Download PDF

Date 11/07/14

Title

Valeant Pharmaceuticals Sends Letter To Physician Customers

Download PDF

Date 11/04/14

Title

Valeant And Pershing Square May Vote At Special Meeting

Download PDF

Date 10/27/14

Title

Valeant Delivers Letter To Allergan Board

Download PDF

Date 10/20/14

Title

Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results

Download PDF

Date 10/15/14

Title

Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October 20, 2014

Download PDF

Date 09/30/14

Title

Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA

Download PDF

Date 09/26/14

Title

Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38%

Download PDF

Date 09/25/14

Title

Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals

Download PDF

Date 09/25/14

Title

Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO™ (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies

Download PDF

Date 09/24/14

Title

Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director

Download PDF

Date 09/15/14

Title

Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017

Download PDF

Date 09/08/14

Title

Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester

Download PDF

Date 08/15/14

Title

Valeant Extends Offer To Acquire Allergan

Download PDF

Date 08/11/14

Title

Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino

Download PDF

Date 08/06/14

Title

Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders

Download PDF

Date 08/01/14

Title

Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit

Download PDF

Date 07/31/14

Title

Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results

Download PDF

Date 07/31/14

Title Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results (pdf version)

Download PDF

Date 07/24/14

Title

Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements

Download PDF

Date 07/21/14

Title

Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements

Download PDF

Date 07/18/14

Title

Valeant Pharmaceuticals Files Investor Presentation

Download PDF

Date 07/17/14

Title

Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure

Download PDF

Date 07/14/14

Title

Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan

Download PDF

Date 07/10/14

Title

Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma

Download PDF

Date 07/08/14

Title

Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology

Download PDF

Date 06/25/14

Title

Valeant Files Preliminary Proxy Statement for Special Meeting of Shareholders to Approve Share Issuance in Proposed Acquisition of Allergan

Download PDF

Date 06/23/14

Title

Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements

Download PDF

Date 06/18/14

Title

Valeant Commences Exchange Offer For Allergan

Download PDF

Date 06/16/14

Title

Valeant Pharmaceuticals Receives U.S. FDA Clearance For Restylane® Silk

Download PDF

Date 06/13/14

Title

Valeant Pharmaceuticals Announces Planned Management Departure

Download PDF

Date 06/13/14

Title

Valeant Pharmaceuticals To Hold Conference Call On Tuesday, June 17, 2014 To Correct Recent Misrepresentations

Download PDF

Date 06/09/14

Title

Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosis

Download PDF

Date 05/30/14

Title

Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiations

Download PDF

Date 05/28/14

Title

Valeant Substantially Increases Merger Proposal For Allergan

Download PDF

Date 05/28/14

Title

Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billion

Download PDF

Date 05/27/14

Title

Valeant To Host In-Person Investor Meeting And Webcast On May 28, 2014 At 8:00 A.M. ET

Download PDF

Date 05/23/14

Title

Valeant Pharmaceuticals to Present at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014

Download PDF

Date 05/21/14

Title

Valeant Pharmaceuticals Announces 2014 Annual Meeting Results

Download PDF

Date 05/20/14

Title

Valeant to Discuss Allergan Proposal at Investor Meeting and Webcast on May 28, 2014 at 8:00 A.M. ET

Download PDF

Date 05/13/14

Title

Valeant Pharmaceuticals Responds to Allergan's Rejection of Merger Proposal

Download PDF

Date 05/12/14

Title

Valeant Pharmaceuticals Enters Into Patent Settlement Agreements With Actavis

Download PDF

Date 05/08/14

Title

Valeant Pharmaceuticals Reports First Quarter 2014 Financial Results

Download PDF

Date 05/01/14

Title

Valeant Pharmaceuticals To Webcast 2014 Annual Meeting Of Shareholders

Download PDF

Date 04/24/14

Title

Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available

Download PDF

Date 04/24/14

Title

Valeant Pharmaceuticals To Announce 2014 First Quarter Results On May 8, 2014

Download PDF

Date 04/23/14

Title

Valeant Pharmaceuticals Announces Nominations For Board Of Directors

Download PDF

Date 04/22/14

Title

Valeant Proposes to Combine With Allergan for $48.30 in Cash and 0.83 Shares of Valeant Stock for Each Allergan Share

Download PDF

Date 03/25/14

Title

Actavis and Valeant Announce FDA Approval for Metronidazole 1.3%

Download PDF

Date 02/27/14

Title

Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results

Download PDF

Date 02/05/14

Title

Valeant Pharmaceuticals To Announce 2013 Fourth Quarter And Full Year Results On February 27, 2014

Download PDF

Date 02/03/14

Title

Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million

Download PDF

Date 01/31/14

Title

Valeant Pharmaceuticals Announces Approval of Retin-A Micro® Microsphere 0.08%

Download PDF

Date 01/23/14

Title

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Solta Medical, Inc.

Download PDF

Date 01/23/14

Title

Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Solta Medical, Inc.

Download PDF

Date 01/22/14

Title

Valeant Pharmaceuticals Announces New $1.5 Billion Securities Repurchase Program

Download PDF

Date 01/15/14

Title

Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.

Download PDF

Investor Inquiries
ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

Media inquiries
Corporate.communications@bauschhealth.com
848-264-0934

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Powered by SITECORE